First-in-Human PET Imaging of Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension Using [18F]ZDG2: Safety, Biodistribution, Dosimetry and Pharmacokinetics
The Methodist Hospital Research Institute
Summary
The goal of this study is to find out whether \[18F\]ZDG2 can detect early blood vessel changes in people with pulmonary arterial hypertension (PAH). The study will help answer this question: Can a positron emission tomography (PET) scan using \[18F\]ZDG2 help identify PAH? Participants will: * Receive one or two doses of the study tracer \[18F\]ZDG2 and have a PET/CT scan after each dose * Provide blood and urine samples * Tell the study team about any side effects or symptoms you experience
Description
Pulmonary arterial hypertension (PAH) affects approximately 220,000 people in the United States and more than 2 million people worldwide. There is currently no cure, and despite available treatments, the five-year mortality rate remains approximately 50%. Diagnosis is often delayed by more than two years because commonly used screening tests lack accuracy, while the gold-standard diagnostic test requires invasive right heart catheterization. By the time PAH is diagnosed, patients may have already lost up to 70% of their pulmonary vascular reserve, resulting in irreversible disease progression.…
Eligibility
- Age range
- 21–75 years
- Sex
- All
- Healthy volunteers
- Yes
Healthy Volunteer Criteria Inclusion Criteria- Healthy Volunteers 1. Age 21-75 years (inclusive) at time of consent 2. Body Mass Index 18.5-35 kg/m² 3. Willing and able to provide written informed consent 4. Willing and able to comply with all study procedures 5. Able to lie flat in supine position for 60 minutes without significant discomfort 6. No history of cardiovascular disease including: * Symptomatic Coronary artery disease * Significant Valvular heart disease (stenotic or regurgative disease of moderate or grater severity) * Congenital heart disease * Symptomatic Arrhyth…
Interventions
- Drug[18F]ZDG2- Single Dose
\[18F\]ZDG2 will be administered as an intravenous injection on the day of imaging. Participants in the reproducibility cohort will receive an additional dose and imaging session one to weeks after the first. Heathy volunteers and PAH patients not in the reproducibility cohort will receive only one dose and imaging session.
Location
- Houston Methodist Research InstituteHouston, Texas